Ensysce Biosciences

Q1 FY2026 EarningsQ2 FY26 results beat consensus on the bottom line despite a revenue miss: EPS (GAAP) of -$0.20 beat the -$0.50 expectation, and net loss of -$2.57M was narrower than the -$3.62M forecast. Federal grant revenue of $1.16M came in below the $1.0M consensus, while R&D expenses rose to $2.5M due to increased clinical activity. A post-quarter acquisition of Cy Biopharma significantly improved the balance sheet, adding ~$31M in net cash and extending the runway into late 2027.